S1PR3 Antibody

What is S1PR3 and why is it an important research target?

S1PR3 (also known as EDG3, S1P3, or LPB3) is a G-protein coupled receptor that belongs to the sphingosine-1-phosphate receptor family. It is a 42 kDa protein that plays crucial roles in:

• Regulation of immune responses

• Vascular integrity and permeability

• Cell migration and proliferation

• Development of a stable and mature vascular system during embryonic development

S1PR3 is of particular interest because it can couple to multiple G proteins (Gq/11, Gi/o, and G12/13), making it a versatile signaling molecule with diverse downstream effects . Its involvement in numerous pathological conditions, including acute lung injury, systemic sclerosis, pulmonary arterial hypertension, and ischemic stroke, makes it an important therapeutic target and biomarker .

How do I select the appropriate S1PR3 antibody for my specific research application?

When selecting an S1PR3 antibody, consider these critical factors:

Always review validation data provided by manufacturers, including positive control samples and expected molecular weight (39-42 kDa for S1PR3) .

What are the optimal conditions for Western blot detection of S1PR3?

Based on published protocols, the following conditions have been successful for S1PR3 detection by Western blot:

Note: EDG3 Antibody detection may show a protein band near 39 kDa rather than the calculated 42 kDa molecular weight, a discrepancy often observed with membrane proteins .

How can I optimize immunofluorescence detection of S1PR3 in tissue samples?

For optimal immunofluorescence detection of S1PR3:

• Fixation: Use 4% paraformaldehyde for 10-15 minutes (cultured cells) or 24 hours (tissue samples)

• Permeabilization: 0.1-0.2% Triton X-100 for 10 minutes for intracellular epitopes

• Antigen retrieval: For formalin-fixed tissues, use citrate buffer (pH 6.0) heat-induced epitope retrieval

• Blocking: 1-5% BSA or 5-10% normal serum from the species of secondary antibody

• Primary antibody incubation: Dilute 1:100-1:500, incubate overnight at 4°C

• Controls: Include both positive controls (tissues known to express S1PR3, such as vascular endothelial cells, astrocytes, and pericytes) and negative controls (primary antibody omission)

• Co-localization markers: Consider co-staining for cell-specific markers:

  • GFAP for astrocytes

  • CD31 for endothelial cells

  • CD13 for pericytes

  • Specific G-protein subunits to study signaling pathway activation

For membrane visualization, use antibodies targeting the N-terminal extracellular domain (AA 23-34) for better surface detection .

How can I verify the specificity of my S1PR3 antibody signal?

To confirm S1PR3 antibody specificity:

• Peptide competition assay: Pre-incubate the antibody with the immunizing peptide before application to samples. Signal should be significantly reduced or eliminated .

• Knockout/knockdown validation: Use samples from S1PR3 knockout animals or cells with siRNA-mediated S1PR3 knockdown as negative controls .

• Multiple antibody approach: Use antibodies recognizing different epitopes of S1PR3 and compare staining patterns .

• Cross-reactivity assessment: Test the antibody on samples from different species to confirm the specificity matches the manufacturer's claims .

• S1PR subtype controls: Test on cells overexpressing other S1P receptors (S1PR1, S1PR2, S1PR4, S1PR5) to confirm no cross-reactivity with related receptors .

• Western blot molecular weight verification: Confirm detection at the expected molecular weight (39-42 kDa) .

What are common issues in S1PR3 detection and how can they be resolved?

For flow cytometry applications, use antibodies targeting extracellular domains (such as N-terminal) and avoid permeabilization for surface detection .

How can S1PR3 antibodies be used to study G-protein coupling selectivity?

To investigate S1PR3 coupling to different G proteins (Gq/11, Gi/o, G12/13), researchers can employ several antibody-based approaches:

• Co-immunoprecipitation (Co-IP):

  • Use S1PR3 antibodies to pull down receptor complexes

  • Probe for associated G protein subunits with specific antibodies

  • Compare interactions before and after stimulation with S1P or synthetic analogues

  • Include controls with S1PR3 antagonists to confirm specificity

• Proximity ligation assays (PLA):

  • Combine S1PR3 antibodies with antibodies against specific G protein subunits

  • Quantify interactions in situ with single-molecule resolution

  • Compare different ligands for biased signaling studies

• Immunofluorescence co-localization:

  • Use S1PR3 antibodies alongside G protein subunit antibodies

  • Track receptor-G protein associations after stimulation with different ligands

  • Assess changes in co-localization with high-resolution microscopy

The crystal structure of S1PR3 revealed that the "quartet core" of residues surrounding the alkyl tail of S1P determines G protein selectivity . Researchers can design studies using antibodies that recognize conformational changes in these regions to investigate biased agonism.

What are the considerations for using S1PR3 antibodies in studying autoimmune conditions?

When studying autoimmune conditions with potential S1PR3 autoantibodies:

• Distinguishing research antibodies from autoantibodies:

  • Use species-specific secondary antibodies to differentiate between exogenous research antibodies and endogenous autoantibodies

  • Include appropriate isotype controls

  • Consider using tagged antibodies that can be specifically detected

• Detecting patient autoantibodies against S1PR3:

  • Develop custom ELISAs using recombinant S1PR3 fusion proteins with luciferase for high sensitivity

  • Test for cross-reactivity with other S1P receptors (S1PR1, S1PR2)

  • Establish threshold values based on healthy control cohorts (as in studies showing <10% prevalence in healthy subjects)

• Functional studies:

  • Compare the effects of commercial antibodies versus patient-derived autoantibodies on S1PR3 signaling

  • Assess receptor internalization, G protein coupling, and downstream signaling

Research has shown elevated S1PR autoantibody prevalence in systemic sclerosis patients (17-27% depending on S1PR subtype) compared to healthy controls (<10%), with further elevation in patients with pulmonary arterial hypertension .

How can S1PR3 antibodies be used to evaluate its potential as a biomarker in acute lung injury and other inflammatory conditions?

S1PR3 has emerged as a promising biomarker in several inflammatory conditions. To evaluate its potential:

• Plasma/serum S1PR3 quantification:

  • Develop sensitive ELISAs using validated S1PR3 antibodies

  • Establish temporal profiles of S1PR3 levels in patients with acute lung injury (ALI)

  • Compare against established biomarkers (IL-1β, IL-6, IL-8, TNF-α)

• Tissue expression studies:

  • Use immunohistochemistry with S1PR3 antibodies to analyze receptor expression in different cell types

  • Quantify changes in expression patterns during disease progression

  • Co-stain with markers of inflammation or cell damage

• Nitrated S1PR3 detection:

  • Develop specific assays using antibodies that recognize nitrated S1PR3

  • Combine with immunoprecipitation to enrich for modified S1PR3

  • Establish correlation with disease severity and outcomes

Research has demonstrated that elevated total S1PR3 plasma concentrations (>251 pg/ml) were linked to sepsis and ALI mortality . Additionally, nitrated S1PR3 has been identified in the plasma of murine ALI models and humans with severe sepsis-induced ALI, suggesting its potential as a specific biomarker reflecting vascular injury .

What methodological approaches can be used to study S1PR3 in ischemic stroke models?

For studying S1PR3 in ischemic stroke:

• Spatiotemporal expression analysis:

  • Use immunohistochemistry with S1PR3 antibodies to track expression changes over time post-stroke

  • Quantify S1PR3 expression in perilesional areas versus distant brain regions

  • Apply cell-type-specific markers to identify which cells upregulate S1PR3 after stroke

• Translatomic approaches:

  • Use RiboTag mouse lines (such as Cnx43 Cre-ER(T)/RiboTag for astrocytes or Cdh5 Cre-ER(T)/RiboTag for endothelial cells)

  • Immunoprecipitate actively translating mRNAs and quantify S1PR3 transcripts

  • Compare with immunostaining results to confirm translation to protein

• In situ hybridization combined with immunofluorescence:

  • Use RNAscope to quantify S1PR3 transcripts at single-cell resolution

  • Combine with S1PR3 immunostaining to correlate mRNA and protein levels

  • Categorize cells based on S1PR3 transcript numbers (e.g., <4, 4-9, 10-15, >15 transcripts per cell)

• Plasma biomarker studies:

  • Use sensitive ELISAs to quantify S1PR3 in plasma during different stages post-stroke

  • Correlate with neurological scores and functional outcomes

  • Compare with other inflammatory markers like C-reactive protein (CRP)

Recent research has shown S1PR3 is acutely upregulated in perilesional reactive astrocytes after stroke, and S1PR3 antagonism at 4 hours post-stroke improved outcomes . Additionally, plasma S1PR3 levels were elevated in both experimental stroke models and human ischemic stroke patients .

How might S1PR3 antibodies contribute to developing new therapeutic approaches?

S1PR3 antibodies can facilitate therapeutic development through several approaches:

• Target validation:

  • Use antibodies to confirm S1PR3 expression in disease-relevant tissues

  • Correlate expression levels with disease severity and outcomes

  • Identify specific cell populations where S1PR3 antagonism might be beneficial

• Therapeutic antibody development:

  • Develop antibodies that bind S1PR3 extracellular domains to antagonize receptor function

  • Screen for antibodies that selectively block coupling to specific G proteins

  • Evaluate antibody-mediated receptor internalization as a therapeutic strategy

• Companion diagnostics:

  • Use antibodies to quantify S1PR3 expression or modification (e.g., nitration) as patient selection biomarkers

  • Develop immunoassays to monitor treatment response

  • Identify patient subpopulations most likely to benefit from S1PR3-targeted therapies

Recent research has shown that S1PR3 antagonism during specific time windows (e.g., 4 hours post-stroke) can improve outcomes in ischemic stroke models , suggesting temporal considerations for therapeutic interventions.

What considerations should be taken into account when developing immunoassays for detecting S1PR3 in clinical samples?

When developing clinical S1PR3 immunoassays:

• Antibody selection criteria:

  • Choose antibodies with validated specificity against native S1PR3

  • Prefer antibodies recognizing conserved epitopes for cross-species studies

  • Consider using antibody pairs that recognize different epitopes for sandwich assays

• Pre-analytical variables:

  • Standardize sample collection procedures (timing, anticoagulants, processing)

  • Assess stability of S1PR3 in different sample types (plasma, serum) and storage conditions

  • Consider microparticle isolation protocols when studying shed receptors

• Calibration and controls:

  • Develop stable recombinant S1PR3 standards

  • Include nitrated S1PR3 standards for specialized assays

  • Establish reference ranges in healthy populations

• Technical validation:

  • Determine assay precision (intra- and inter-assay variability)

  • Establish limits of detection and quantification

  • Assess potential interfering substances

• Clinical validation:

  • Compare with established biomarkers

  • Evaluate prognostic value in longitudinal studies

  • Determine specificity for particular disease states

Research has shown that S1PR3 can be shed in microparticles , and that nitrated S1PR3 may have specific pathological significance , suggesting that assays designed to detect these specific forms may have enhanced clinical value.